McQuibban Lab and Cyclica to Discover Experimental Drugs for Neurodegenerative Diseases
This post was adapted from its original source on Ontario Genomics’ news page and can be viewed here. Validating and Improvement of in silico Proteome Screening and Drug Design Technologies by Experimental Drug Discovery for Neurodegenerative Diseases PROJECT LEADERS: ANGUS MCQUIBBAN (UNIVERSITY OF TORONTO), ZHENG LI (CYCLICA INC.) GENOME CENTRE: ONTARIO GENOMICS TOTAL PROJECT FUNDING: $2.3 MILLION TORONTO, […]
Stagljar Lab and Cyclica team up to tackle treatment-resistant lung cancer
This post was adapted from its original source on the University of Toronto’s News page and can be viewed here. TORONTO, CANADA (July 22, 2019) – Igor Stagljar, a professor at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research, and Toronto-based biotechnology company Cyclica have launched a partnership to advance treatment of […]
Cyclica Launches Ligand Design™, a Powerful Multi-Targeted Drug Design Technology at Collision Conference Toronto
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA – (May 22, 2019) – Cyclica, a leading biotechnology company that commercialized Ligand Express® announced its novel, first-in-class drug design technology, Ligand DesignTM on stage at the Collision Conference in Toronto. This revolutionary platform empowers scientists in the […]
Cyclica Announces the Integration of the POEM Machine Learning Predictive Engine in their Ligand Express® Platform
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO, CANADA – (May 17, 2019) – Cyclica, a leading biotechnology company that leverages artificial intelligence and computational biophysics to enable the discovery of new medicines, has announced the addition of a machine learning predictive engine called POEM to its […]
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI Augmented Screening Platform to Expand Research Capabilities
This post was adapted from its original source on Cision PR Newsire and can be viewed here. Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles Evaluation to include identification of potential mechanisms of action for investigational small […]
Cyclica Drives Drug Discovery Through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer
This post was adapted from its original source on Business Wire and can be viewed here. TORONTO —(BUSINESS WIRE)— Cyclica (https://www.cyclicarx.com/), a Bayer G4A company, is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling […]
Cyclica’s cloud-based platform will help new discovery efforts in bioactive products
TORONTO, ON, CANADA (October 24, 2018) – Cyclica (www.cyclicarx.com) is pleased to announce that, through the Build in Canada Innovation Program (BCIP), a team of scientists from the National Research Council of Canada (NRC) (www.nrc-cnrc.gc.ca/eng/) will have access to Ligand Express®—Cyclica’s cloud-based platform. Accessing Ligand Express will help advance new discovery efforts at the NRC, particularly […]
Eurofarma and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies
TORONTO, ON, CANADA (October 8, 2018) – Eurofarma (https://www.eurofarma.com.br/en/), and Cyclica (https://www.cyclicarx.com/) are pleased to announce a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology. Through a multi-phase collaboration, Eurofarma will leverage Cyclica’s cloud-based proteome screening platform, Ligand Express®, to investigate the off-target profiles of small molecules, apply Cyclica’s novel […]
Alliance for Artificial Intelligence in Healthcare (AAIH) Convenes in Boston and Basel to Announce Mission and Launch Activities
This post was adapted from its original source on Business Wire and can be viewed here. Leaders in AI for Healthcare applications have come together to form a global organization to educate and advocate for policies and regulations to promote rapid integration and utilization of AI in healthcare WASHINGTON —(BUSINESS WIRE)— The founding members of […]
Cyclica Joins Bayer G4A to Advance its Novel Differential Drug Design Technology
TORONTO, ON, CANADA (August 30, 2018) – Cyclica (www.cyclicarx.com) is thrilled to announce that it has joined Bayer G4A as one of six finalists selected from over 1800 applicants globally this year. In November 2017, Cyclica introduced a first-in-class-proteome screening technology as part of Ligand Express, which is actively being used by scientists at leading […]